Indications and results of resection for hepatocellular carcinoma

Ziparo, V.; Balducci, G.; Lucandri, Giorgio; Mercantini, Paolo; Giacomo, Giuseppe Di; Fernandes, Eduardo de Souza Martins

doi:10.1053/ejso.2002.1299

Cited by 46 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although an accurate selection of patient eligible to resection, advances in surgical techniques, and perioperative management have greatly contributed to lower the rate of perioperative deaths, stress must be put on reducing the postoperative complication rates reported to be still as high as 50% [13][14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Benzoni

Cojutti

Lorenzin

et al. 2006

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…With the advances in surgical techniques and perioperative management, inhospital mortality and morbidity, in consequence of liver resection, have greatly improved [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Benzoni

Cojutti

Lorenzin

et al. 2006

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…It should be noted that these data categorise patients according to the primary liver disease specified at the time of listing; this has the important implication that the 'HCC' category represents a minority of patients with tumours on 176,178,179,190,193,[415][416][417][418][419][420][421] • 11 insufficient sample size (n < 50) 171,172,186,205,411,[422][423][424][425][426][427] • Four included a substantial proportion of non-cirrhotic cases 155,165,428,429 • Five included a substantial proportion of large tumours (>5 cm) 166 …”

Section: Waiting List For Liver Transplantationmentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

152

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

“…In spite of the great developments in diagnosis and therapy, the prognosis for patients with HCC remains dismal due to its high rate of metastasis and recurrence. For patients in the advanced stages, the median survival rate is less than 6 months, regardless of the type of the treatment modality used (4).…”

Section: Introductionmentioning

confidence: 99%

Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo

et al. 2012

View full text Add to dashboard Cite

Abstract. Hepatocellular carcinoma is a common type of cancer that is usually associated with poor prognosis. In this study, we examined the in vitro and in vivo mechanisms of the traditional Vietnamese herb Zanthoxylum avicennae on the inhibition of HA22T human hepatocellular carcinoma cell proliferation. HA22T cells were treated with different concentrations of Zanthoxylum avicennae extracts (YBBEs) and analyzed with the MTT assay, western blot analysis, flow cytometry, siRNA transfection assays and co-immunoprecipitation assay. Additionally, the HA22T-implanted xenograft nude mouse model was applied to confirm the cellular effects. YBBEs showed a strong inhibition of HA22T cell viability in a dose-dependent manner and significantly reduced cell proliferation-related proteins as well as induced cell cycle arrest in the G2/M phase. Protein phosphatase 2A (PP2A) siRNA or okadaic acid totally blocked YBBE-mediated cell proliferation inhibition. In addition, an HA22T-implanted nude mouse model further confirmed that YBBEs inhibit HA22T tumor cell growth and downregulate the survival and cell cycle regulating proteins, as well as activate the PP2A protein. Our findings indicate that the inhibition of HA22T cell proliferation by YBBEs is mediated through PP2A activation.

show abstract

Indications and results of resection for hepatocellular carcinoma

Cited by 46 publications

References 32 publications

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo

Contact Info

Product

Resources

About